If HP wants to become one of the companies of the future, they have to make major changes to their BM. We will be moving from virtual reality of FB and GOOG, somewhat AAPL to the real world of making things faster. Two front runners: SSYS (and somewhat DDD with the exception of quality!) and IRBT (AVAV somewhat). Let's make some money in BOX and DropBox soon and move back to these great companies. MY guess is that HP will make a move around June.
You have no idea about NovaBay's chemical compounds. They have a low pH bleach that they claim kills bacteria better than bleach. This is the old bleach plus vinegar grandma type of solution!
Their other compound is the result of mixing bleach with amino acid. All they have is very similar or derived from bleach and Cl.
Please educate yourself first and change your diaper!
Alcon trial failed, NBY thinks that they can repeat and get "GOOD DATA"
Galderma trials failed, NBY says that they can repeat and get "GOOD DATA"
Note: the trials are being conducted in "BRAZIL"!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Those who think that the bleach that Pioneer has marketing rights is a new thing, please see VASHE which has been around for a long time and Pioneer not aware of its existance. The question is how much money can this make? Is it stable as defined by the FDA and how it is delivered? VASHE is in plastic bottles and NBY product in glass!!! I am not sure why. Bleach is more stable in some plastic than glass since glass will help degradation of bleach. Almost everyone knows this.
Galderma is in bad shape. Their produts are becomeing generic, no new drug in their pipeline and the impetigo failed!!!
Was the placebo better? They are not talking.
I have done my homework. I have made above $60000 in shorts with NBY. Here the list of their operations:
NVC-101 (Now Nurophase or something): clinical trial in wound healing failed (no press release)
NVC-422 (Now aurochlorsin or something): Nasal decolonization trials failed (no press release)
NVC-422: Prevention of common cold: clinical trial failed, no press release.
NVC-422: collaboration with Alcon in viral eye infection failed: press release, they are repeating the trial!!!
NVC-422: Acne trial with Galderma: clinical trial failed, no press release.
NVC-422: Impetigo with Galderma, failed we are waiting for Galderma to decide what to DO!!!!!!!!!!!!1
NVC-422: urinary catheter blockage: who knows! so far no takers!!!
Commercialization of Neutrophase: not a penny of profit so far!!!!!!!!!!!!!!!!!!!!!
Up and Down, Up and Down!
What happened to the huge sales predictions for any of these POS?
Are you all ready for a FA!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!?
The shorts thinking: I need this to go up so I can short more!
The pumpers thinking: I need this to go up so I can make more money by buying/selling and SHORTING!!
Those who believe them: IDIO@@@
Please refresh my memory: NBY has no solid income anymore, just huge expense, is that right?
The eye infections study by Alcon failed (NBY is REPEATING it!!), is that right?
The impetigo study with GAlderma, the only paying partner, JUST FAILED?
The market for the urinary blockage is very small, no partner?
Shorts need high volume and too high for price (100000/day, $1.20)
Bleach is being sold by CVS and it works, I don't think that a fancy version will be needed!!!
Bleach is not a DRUG. This is a topical only product (as NBY says), can not be injected, taken as an oral solution, etc. It has failed a major Alcon eye trial and now the skin! I think the only thing left is for the Executive to put it in their A@@
You can hear the investor call (Roche doesn't issue Q3) . 7% growth, major growth in US. EU only 2%. Japan 3%. China great growth. NO specific talk on Erivedge sales (since it is not top 20 Roche drug). If we graph the trends, we will have at least 10% growth and I think few bulk payments. The Q3 report by CRIS should help push the share price to 5.0. Some clinical results will be expected before 2014.
If I don't forget, I will post the numbers a day ahead. I think early Nov.
You can Google "CAR FIRE BMW" or Audi or BENZ and see how the passenger seats catch fire and kill!
The Tesla on fire (if not a set up) did NOT get to the passengers. This shows that the design of TESLA is safer than any of the major brands.
I saw the video and I would say that it was very questionable and suspicious. The short interests are very high and they might have bought a used Tesla, planned the fire with good calculations and video taped it. I think that is highly suspicious that the persons taking that tape were interested in the car model and not if anyone got hurt.
Why anyone sells two days prior to a big press release by NBY?
This guy knows something we don't. If I were you, I will carefully read everything related or coming from NBY.
It is not Najari, it it Najafi. Najari is a very nice guy, he is not a criminal, he is honest and doesn't manipulate clinical data or lie to the inverstors, employees and his own family. Please correct your post.
A friend of Najari in NY